Pharmafile Logo

Global Value Dossier

regeneron headquarters

Regeneron’s odronextamab recommended by CHMP to treat certain lymphomas

Follicular lymphoma and diffuse large B-cell lymphoma are collectively responsible for an estimated 283,000 global cases every year

- PMLiVE

Merck’s pulmonary arterial hypertension therapy receives CHMP recommendation

Approximately 30,000 people in the EU are currently living with the rare blood disorder

- PMLiVE

Dementia – risk factors, research and treatment

There are over ten million new cases of dementia each year worldwide, which translates into one new case every 3.2 seconds

- PMLiVE

Surrogate endpoints in HTA: Reflections on my HTAi panel discussion

Calum Jones (Associate Director – Health Economics, Mtech Access) shares his experience of speaking at the 2024 HTAi Annual Meeting. Calum participated in the panel discussion: ‘Surrogate Endpoints in Health...

Petauri Evidence

- PMLiVE

US and European Market Access for Medical Devices – Free Guide

We are delighted to announce that the second edition of our popular introductory guide: ‘Market access stakeholders and processes for medical devices in key European markets’ is now available. Our...

Petauri Evidence

Say Goodbye to Costly Delays – Origins’ Clinical Trial Participant Simulations Have the Answer!

Lack of Patient Involvement in Clinical Trial Designs Causes Major Issues Low recruitment and retention of clinical trials is a key issue faced by many clinical trials. These can lead...

Origins – The Patient Focused Specialists

- PMLiVE

FDA approves Samsung Bioepis’ Stelara biosimilar Pyzchiva for inflammatory conditions

The drug has been authorised to treat plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis

- PMLiVE

AstraZeneca’s Imfinzi/Lynparza regimen recommended by CHMP to treat endometrial cancer

Almost 125,000 cases of endometrial cancer were diagnosed in Europe in 2022

- PMLiVE

Eli Lilly and Radionetics Oncology enter $140m radiopharma partnership

The strategic agreement also gives Lilly the exclusive right to acquire the biotech for $1bn

- PMLiVE

Roche announces CHMP recommendation for PiaSky in rare blood condition PNH

Paroxysmal nocturnal haemoglobinuria affects approximately 20,000 people worldwide

- PMLiVE

Almirall’s Ilumetri shown to improve and maintain well-being in plaque psoriasis patients

Nearly 77% of psoriasis patients report that the condition negatively affects their well-being

- PMLiVE

Find your brand’s edge, with dynamic competitive simulations

How the best teams in pharma stay at the top of their game

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links